Biodel PT Raised to $9.00 (BIOD) (Mideast Time)
Biodel had its price target increased by JMP Securities from $6.00 to $9.00 in a research report sent to investors on Thursday morning, StockRatingsNetwork.com reports. Shares of Biodel Inc (NASDAQ:BIOD) traded up 12.08% during mid-day trading on Thursday, hitting $5.335. The stock had a trading volume of 1,185,247 shares. Biodel has a one year low of $2.13 and a one year high of $6.08. The stock has a 50-day moving average of $4.56 and a 200-day moving average of $3.52. The company’s market cap is $100.8 million.
Supernus shares jump on epilepsy drug approval (MSN Money)
Shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) jumped Monday after the company said that its epilepsy treatment was approved by government regulators. The Rockville, Md.-based company said that it received a final approval letter from the Food and Drug Administration for Trokendi XR, an extended-release treatment for epilepsy that is taken once daily. Shares rose 62 cents, or 9.3 percent, to $7.26 Monday afternoon. Through Friday, the share had gained 49 percent from a 52-week low of $4.45 in April.
Our BioPharma Catalyst Watch List (Proactive Investors USA & Canada)
Biodel Inc (NASDAQ:BIOD) is a biopharmaceutical company that focuses on the development and specialization of treatments for diabetes. Biodel’s leading drug candidate is BIOD-123, which is an ultra-rapid acting insulin formulation. Biodel has recently been gaining a lot of attention because it has a market cap of under $100M, while the global diabetes market is worth over $10B. Biodel is expecting to release results from a Phase II trial in the third quarter of 2013.
Supernus Gets FDA Approval for Extended-Release Epilepsy Treatment Trokendi XR (Wall Street Journal)
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) said the U.S. Food and Drug Administration gave final approval for its extended-release epilepsy treatment, which the specialty drug maker expects to roll out over the next few weeks. The latest approval is for Trokendi XR, a once-a-day formulation of topiramate. The FDA also granted a waiver for certain pediatric study requirements and a deferral for submission of post-marketing pediatric pharmacokinetic assessments that are due in 2019 followed by clinical assessments in 2025.